Home LiteratureArticle Details
PMID: 1695589 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Inhibition of insulin and somatostatin secretion and stimulation of glucagon release by homologous galanin in perfused rat pancreas.

Diabetes ·Vol. 39 ·No. 8 ·1990-08-00 ·Pages 996-1001

Miralles P, Peiró E, Dégano P, Silvestre RA, Marco J

Abstract

Results of studies on the effects of exogenous galanin on islet cell secretion are controversial. Until recently, only pig galanin has been available, and structural dissimilarities among the galanin molecules of different species might have contributed to discrepancies among the study results. Thus, we investigated the influence of synthetic rat galanin (50 nM) on unstimulated insulin, glucagon, and somatostatin release and on the responses of these hormones to arginine (10 mM), glucose (16.6 mM), and vasoactive intestinal polypeptide (VIP; 1 nM) in a homologous animal model, the perfused rat pancreas. In addition, the effect of an equimolar concentration of pig galanin on arginine-induced islet cell secretion was examined. Infusion of rat galanin reduced unstimulated insulin release (approximately 60%, P less than 0.01) and the insulin responses to arginine (approximately 30%, P less than 0.025), glucose (100%, P less than 0.01), and VIP (approximately 80%, P less than 0.025). Galanin also inhibited unstimulated somatostatin secretion (approximately 15%, P less than 0.05) and virtually abolished the somatostatin output evoked by arginine, glucose, and VIP. Conversely, rat galanin increased unstimulated glucagon output (approximately 20%, P less than 0.05), potentiated the glucagon response to arginine (approximately 50%, P less than 0.05) and VIP (approximately 90%, P less than 0.05), and counteracted the suppressor effect of glucose on alpha-cell secretion. Pig galanin inhibited the insulin output elicited by arginine (approximately 45%, P less than 0.05) but did not affect the somatostatin and glucagon responses to the aminogenic stimulus. In conclusion, the opposite effects of galanin on insulin and glucagon secretion favor the concept of galanin as a diabetogenic agent. Galanin also behaves as a potent inhibitor of somatostatin release. Finally, the importance of using homologous galanin to study the biological activity of this peptide must be emphasized.

MeSH Terms
Animals Arginine/pharmacology Dose-Response Relationship, Drug Galanin Glucagon/metabolism Glucose/pharmacology Insulin/metabolism Insulin Secretion Male Pancreas/drug effects,metabolism Peptides/administration & dosage,pharmacology Perfusion Rats Rats, Inbred Strains Somatostatin/metabolism Vasoactive Intestinal Peptide/pharmacology
Chemicals
Insulin Peptides Vasoactive Intestinal Peptide Somatostatin Galanin Glucagon Arginine Glucose
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Miralles P
Hospital Puerta de Hierro, Universidad Autonama de Madrid, Spain.
Peiró E
Dégano P
Silvestre R A
Marco J
Article Info
Journal
Diabetes
Abbr.
Diabetes
ISSN
0012-1797
Published
1990-08-00
Pages
996-1001
Language
English
Region
United States
NLM ID
0372763
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com